Literature DB >> 908151

Increased prolactin and thyrotrophin secretion following oral metoclopramide: dose-response relationships.

D L Healy, H G Burger.   

Abstract

Four normal men received 1, 5, 10 and 20 mg doses of oral metoclopramide, a dopamine receptor antagonist, or placebo to determine the effect of this drug on anterior pituitary hormone secretion. Increases in serum prolactin (PRL) occurred even after the 1 mg tablet (P less than 0.01) while maximal responses were observed 60 min after ingestion of the 20 mg tablet (mean 27.8 ng/ml; range 25.6-30.3 ng/ml). Serum PRL levels peaked 60-90 min after ingestion of any dose of metoclopramide and values remained significantly elevated (P less than 0.05) for up to 8h after the tablet. Increases in serum thyrotrophin (TSH) also occurred after the 10 and 20 mg doses of metoclopramide. Peak responses were seen at 120-180 min, with significant elevation (P less than 0.05) persisting from 60 to 240 min after ingestion. No consistent changes in serum FSH, LH or GH were observed and no side-effects were reported. It was concluded that metoclopramide elevated serum PRL and TSH. The threshold dose of metoclopramide required for these effects was different for the two hormones; their peak responses occurred at different times and the duration of the elevation was dissimilar, suggesting a mechanism other than the release of hypothalamic thyrotrophin-releasing hormone (TRH).

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 908151     DOI: 10.1111/j.1365-2265.1977.tb01315.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  11 in total

Review 1.  Some current aspects of clinical and experimental neuroendocrinology with particular reference to growth hormone, thyrotropin and prolactin.

Authors:  M F Scanlon; M Pourmand; A M McGregor; M D Rodriguez-Arnao; K Hall; A Gomez-Pan; R Hall
Journal:  J Endocrinol Invest       Date:  1979 Jul-Sep       Impact factor: 4.256

2.  Metoclopramide-induced reversible impotence.

Authors:  R G Berlin
Journal:  West J Med       Date:  1986-03

Review 3.  Neuroendocrine markers of CNS drug effects.

Authors:  E C Johnstone; I N Ferrier
Journal:  Br J Clin Pharmacol       Date:  1980-07       Impact factor: 4.335

4.  In vitro studies on TSH secretion and adenylate cyclase activity in a human TSH-secreting pituitary adenoma. Effects of somatostatin and dopamine.

Authors:  A Spada; M Bassetti; E Martino; G Giannattasio; P Beck-Peccoz; A Sartorio; L Vallar; L Baschieri; A Pinchera; G Faglia
Journal:  J Endocrinol Invest       Date:  1985-06       Impact factor: 4.256

5.  Estrogenic treatment does not modify the TSH and PRL responses to domperidone and TRH in patients with tumoral hyperprolactinemia.

Authors:  E Ghigo; G Pogliano; C Campagnoli; A Bertagna; F Camanni; F Massara
Journal:  J Endocrinol Invest       Date:  1984-10       Impact factor: 4.256

6.  Hypothalamo-pituitary-thyroid function in anorexia nervosa: influence of weight gain.

Authors:  R D Leslie; A J Isaacs; J Gomez; P R Raggatt; R Bayliss
Journal:  Br Med J       Date:  1978-08-19

7.  Effect of metoclopramide on maternal and fetal hyperprolactinemia.

Authors:  G Robuschi; R Emanuele; L d'Amato; M Salvi; E Dall'Aglio; E Gardini; M Fatone; S Foscolo; A Gnudi; E Roti
Journal:  J Endocrinol Invest       Date:  1983-04       Impact factor: 4.256

Review 8.  Neuroendocrine regulation of thyrotropin-releasing hormone (TRH) in the tuberoinfundibular system.

Authors:  R Toni; R M Lechan
Journal:  J Endocrinol Invest       Date:  1993-10       Impact factor: 4.256

Review 9.  Domperidone. A review of its pharmacological activity, pharmacokinetics and therapeutic efficacy in the symptomatic treatment of chronic dyspepsia and as an antiemetic.

Authors:  R N Brogden; A A Carmine; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1982-11       Impact factor: 9.546

10.  Prolactin response to exercise, metoclopramide and other provacative agents in children.

Authors:  K Ijaiya
Journal:  Eur J Pediatr       Date:  1980-09       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.